Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Cidara Therapeutics, Inc. (Nasdaq: CDTX) announced the upcoming presentation by CEO Jeffrey Stein, Ph.D., at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be accessible on-demand via the Investors section of the company’s website starting March 9, 2021. Cidara is focused on developing long-acting therapeutics to improve care for patients with serious fungal and viral infections, with its lead antifungal candidate being rezafungin and additional antiviral conjugates from the Cloudbreak® platform.

News Market Reaction – CDTX

-3.88%

-3.88% Session move

In the trading session that priced this news, CDTX declined 3.88%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.cidara.com.

About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Karen O’Shea, Ph.D.
LifeSci Communications
(929) 469-3860
koshea@lifescicomms.com

FAQ

When is Cidara Therapeutics presenting at the H.C. Wainwright Conference?

Cidara Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Where can I watch the Cidara Therapeutics presentation?

The Cidara Therapeutics presentation will be available on-demand on their website starting March 9, 2021.

What are Cidara Therapeutics’ main products?

Cidara Therapeutics is developing long-acting therapeutics including the antifungal candidate rezafungin and antiviral conjugates for influenza and other viral diseases.

What is the focus of Cidara Therapeutics?

Cidara Therapeutics focuses on developing therapies for serious fungal and viral infections.

What is the stock symbol for Cidara Therapeutics?

The stock symbol for Cidara Therapeutics is CDTX.